WO2016058467A1 - Method for preparing tedizolid phosphate - Google Patents

Method for preparing tedizolid phosphate Download PDF

Info

Publication number
WO2016058467A1
WO2016058467A1 PCT/CN2015/089734 CN2015089734W WO2016058467A1 WO 2016058467 A1 WO2016058467 A1 WO 2016058467A1 CN 2015089734 W CN2015089734 W CN 2015089734W WO 2016058467 A1 WO2016058467 A1 WO 2016058467A1
Authority
WO
WIPO (PCT)
Prior art keywords
phosphate
compound
preparing
pyridine
methyltetrazol
Prior art date
Application number
PCT/CN2015/089734
Other languages
French (fr)
Chinese (zh)
Inventor
许学农
Original Assignee
苏州明锐医药科技有限公司
哲人药业南京有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 苏州明锐医药科技有限公司, 哲人药业南京有限公司 filed Critical 苏州明锐医药科技有限公司
Publication of WO2016058467A1 publication Critical patent/WO2016058467A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/582Recycling of unreacted starting or intermediate materials

Definitions

  • the invention belongs to the technical field of organic synthesis route design and preparation technology of raw materials and intermediates, and particularly relates to a preparation method of a novel oxazolidinone antibiotic phosphotidazole.
  • Tedizolid phosphate is an oxazolidinone antibiotic developed by Cubist Pharmaceuticals. Tedizolid phosphate was approved by the US FDA in June 2014 and is marketed under the trade name Sivextro. This drug is the first second-generation oxazolidinone antibiotic to be approved by the FDA. Compared with the first-generation product linezolid, Sivextro has 2-8 times higher inhibitory activity against some bacteria, and the safety is also somewhat Improved. Since the compound Tedizolid does not yet have a standard Chinese translation, the applicant hereby transliterates it as "tedizamide.”
  • Tedizolid phosphate is ⁇ (5R)-3-[3-fluoro-4-[6-(2-methyl-2H-tetrazole-5-yl)pyridine-3- Phenyl]-2-oxazol-5-yl ⁇ methanol phosphate (I), the structural formula is:
  • 2-(2-methyltetrazol-5-yl)-5-bromopyridine (Intermediate A) is an azide via 2-cyano-5-bromopyridine
  • the reaction produces a tetrazolyl derivative, and the methylation reagent such as methyl iodide or dimethyl sulfate is used to methylate the tetrazole ring to obtain 2-(2-methyltetrazole-5- a mixture of 5-bromopyridine (intermediate A) and 2-(1-methyltetrazol-5-yl)-5-bromopyridine (by-product), which is isolated by column chromatography or recrystallization.
  • the methylation reagent such as methyl iodide or dimethyl sulfate
  • the intermediate B or B' is an organotin reagent or an organoboron reagent prepared by R-3-(3-fluoro-4-iodophenyl)-2-oxo-5-oxazolidinemethanol, which is passed through The Stille or Suzuki coupling reaction allows coupling to Intermediate A.
  • the existing preparation methods have weaknesses such as long preparation steps, difficult to obtain raw materials, and high cost; the preparation and use of organotin reagents have high requirements on equipment and environment, and there are hidden dangers of environmental pollution. Further, the simultaneous presence of fluorine and iodine of the halogen in the intermediate B or B' structure lowers the selectivity in the formation of the organometallic reagent, increases the side reaction, and makes it difficult to effectively control the product quality.
  • the object of the present invention is to provide a preparation method of teridinamine phosphate which is easy to obtain raw materials, simple in process, economical and environmentally friendly, and suitable for industrialization, in view of the defects in the prior art.
  • the present invention adopts the following main technical solutions: a preparation method of teridinamine phosphate (I),
  • the preparation step comprises the steps of: coupling a compound of the formula II with a compound of the formula III to form teridinamine (I).
  • R is hydrogen, methyl, ethyl, propyl, isopropyl, phenyl or pinacol
  • the corresponding compound of formula II is 2-(2-methyltetrazol-5-yl).
  • Pyridine-5-boric acid dimethyl 2-(2-methyltetrazol-5-yl)pyridine-5-borate, 2-(2-methyltetrazol-5-yl)pyridine-5-borate Ethyl ester, 2-(2-methyltetrazol-5-yl)pyridine-5-borate dipropyl ester, 2-(2-methyltetrazol-5-yl)pyridine-5-borate diisopropyl ester, 2-(2-methyltetrazol-5-yl)pyridine-5-boronic acid diphenyl ester or 2-(2-methyltetrazol-5-yl)pyridine-5-boronic acid pinamate.
  • the halogen X in the compound of the formula III is bromine or iodine, and the corresponding compound of the formula III is, in turn, R-3-(3-fluoro-4-bromo-phenyl)-2-oxo-5-oxazolidinylalkylmethanol Phosphate or R-3-(3-fluoro-4-iodo-phenyl)-2-oxo-5-oxazole alkyl methanol phosphate.
  • the molar ratio of the compound of the formula II to the compound of formula III in the coupling reaction is from 1:0.5 to 1.5, preferably from 1:0.9 to 1.1.
  • the catalyst for the coupling reaction is palladium chloride, palladium acetate, bis(dibenzylideneacetone)palladium, tetrakis(triphenylphosphine)palladium, [1,1'-bis(diphenylphosphino)ferrocene Palladium dichloride, bis(tricyclohexylphosphine)palladium dichloride or bis(triphenylphosphine)palladium dichloride, preferably tetrakis(triphenylphosphine)palladium or [1,1'-bis(diphenyl) Phosphine) ferrocene] palladium dichloride.
  • the base promoter of the coupling reaction is potassium carbonate, sodium carbonate, barium carbonate, barium fluoride, potassium acetate or potassium phosphate, preferably barium carbonate or potassium phosphate.
  • the solvent for the coupling reaction is acetonitrile, 1,4-dioxane, toluene, xylene, N,N-dimethylformamide, N,N-dimethylacetamide or dimethyl sulfoxide, preferably 1,4-dioxane or toluene.
  • the temperature of the coupling reaction is from 50 to 150 ° C, preferably from 80 to 130 ° C.
  • the preparation method of the teridinamine phosphate (I) according to the invention has the characteristics of easy availability of raw materials, simple process and environmental protection economy, thereby facilitating the industrial production of the raw material drug and promoting its economic technology. development of.
  • Embodiment 1 is a diagrammatic representation of Embodiment 1:
  • Embodiment 2 is a diagrammatic representation of Embodiment 1:
  • Embodiment 3 is a diagrammatic representation of Embodiment 3

Abstract

Disclosed is a method for preparing tedizolid phosphate (I), and the preparation step thereof comprises producing the tedizolid phosphate (I) by means of a coupling reaction of a compound of formula II and a compound of formula III. The preparation method uses easily available raw materials and a simple process, is economical and environmentally friendly, and is suitable for industrial production.

Description

磷酸泰地唑胺的制备方法Method for preparing tertimazine phosphate 技术领域Technical field
本发明属于有机合成路线设计及其原料药和中间体制备技术领域,特别涉及一种新的噁唑烷酮类抗菌素磷酸泰地唑胺的制备方法。The invention belongs to the technical field of organic synthesis route design and preparation technology of raw materials and intermediates, and particularly relates to a preparation method of a novel oxazolidinone antibiotic phosphotidazole.
背景技术Background technique
Tedizolid phosphate是由卡毕斯特(Cubist)制药公司开发的一种噁唑烷酮类抗生素。Tedizolid phosphate于2014年6月获得美国FDA批准在美国上市,商品名为Sivextro。该药是第一个获得FDA批准的二代噁唑烷酮类抗生素,和一代产品利奈唑胺相比,Sivextro对一些细菌的体外抑制活性要高2-8倍,安全性在一定程度上也有所提高。因化合物Tedizolid还不具有标准的中文译名,故本申请人在此将其音译为“泰地唑胺”。Tedizolid phosphate is an oxazolidinone antibiotic developed by Cubist Pharmaceuticals. Tedizolid phosphate was approved by the US FDA in June 2014 and is marketed under the trade name Sivextro. This drug is the first second-generation oxazolidinone antibiotic to be approved by the FDA. Compared with the first-generation product linezolid, Sivextro has 2-8 times higher inhibitory activity against some bacteria, and the safety is also somewhat Improved. Since the compound Tedizolid does not yet have a standard Chinese translation, the applicant hereby transliterates it as "tedizamide."
磷酸泰地唑胺(Tedizolid phosphate)的化学名为:{(5R)-3-[3-氟-4-[6-(2-甲基-2H-四唑-5-yl)吡啶-3-基]苯基]-2-噁唑酮-5基}甲醇磷酸酯(I),其结构式为:The chemical name of Tedizolid phosphate is {(5R)-3-[3-fluoro-4-[6-(2-methyl-2H-tetrazole-5-yl)pyridine-3- Phenyl]-2-oxazol-5-yl}methanol phosphate (I), the structural formula is:
Figure PCTCN2015089734-appb-000001
Figure PCTCN2015089734-appb-000001
磷酸泰地唑胺的制备方法已有研究报道,PCT专利第WO2005058886号、第WO2010042887号和《European Journal of Medicinal Chemistry》2011年第46期第1027~1039页均报道了磷酸泰地唑胺及其类似物以及相关中间体的合成方法。对比总结这些方法,其合成路线均是由中间体A和中间体B(或中间体B’)通过芳基偶联反应来实现。The preparation method of ticlopamide is reported. PCT Patent No. WO2005058886, WO2010042887 and European Journal of Medicinal Chemistry, No. 46, 2011, pages 1027 to 1039, have reported tertidamine phosphate and its Methods for the synthesis of analogs and related intermediates. These methods are compared and summarized, and their synthetic routes are all achieved by the intermediate coupling reaction of intermediate A and intermediate B (or intermediate B').
Figure PCTCN2015089734-appb-000002
Figure PCTCN2015089734-appb-000002
其中2-(2-甲基四唑-5-基)-5-溴吡啶(中间体A)是通过2-氰基-5-溴吡啶的叠氮 化反应生成四氮唑基衍生物,再利用碘甲烷或硫酸二甲酯等甲基化试剂,对四氮唑环进行甲基化反应,制得2-(2-甲基四唑-5-基)-5-溴吡啶(中间体A)和2-(1-甲基四唑-5-基)-5-溴吡啶(副产物)的混合物,经柱层析或重结晶分离得到中间体A。Wherein 2-(2-methyltetrazol-5-yl)-5-bromopyridine (Intermediate A) is an azide via 2-cyano-5-bromopyridine The reaction produces a tetrazolyl derivative, and the methylation reagent such as methyl iodide or dimethyl sulfate is used to methylate the tetrazole ring to obtain 2-(2-methyltetrazole-5- a mixture of 5-bromopyridine (intermediate A) and 2-(1-methyltetrazol-5-yl)-5-bromopyridine (by-product), which is isolated by column chromatography or recrystallization. A.
Figure PCTCN2015089734-appb-000003
Figure PCTCN2015089734-appb-000003
中间体B或B’是通过R-3-(3-氟-4-碘苯基)-2-氧代-5-噁唑烷基甲醇制成的有机锡试剂或有机硼试剂,该试剂通过Stille或Suzuki偶联反应,实现与中间体A的偶联。The intermediate B or B' is an organotin reagent or an organoboron reagent prepared by R-3-(3-fluoro-4-iodophenyl)-2-oxo-5-oxazolidinemethanol, which is passed through The Stille or Suzuki coupling reaction allows coupling to Intermediate A.
Figure PCTCN2015089734-appb-000004
Figure PCTCN2015089734-appb-000004
由此看出,现有的制备方法存在制备步骤长、原料难以获得以及成本较高等弱点;有机锡试剂的制备和使用对设备和环境要求都比较高,存在环境污染隐患。另外,中间体B或B’结构中卤素的氟和碘的同时存在,降低了有机金属试剂形成时的选择性,使副反应增多,产品质量难以得到有效控制。It can be seen that the existing preparation methods have weaknesses such as long preparation steps, difficult to obtain raw materials, and high cost; the preparation and use of organotin reagents have high requirements on equipment and environment, and there are hidden dangers of environmental pollution. Further, the simultaneous presence of fluorine and iodine of the halogen in the intermediate B or B' structure lowers the selectivity in the formation of the organometallic reagent, increases the side reaction, and makes it difficult to effectively control the product quality.
发明内容Summary of the invention
本发明的目的在于针对现有技术中的缺陷,提供一种具有原料易得、工艺简洁、经济环保且适合工业化的磷酸泰地唑胺的制备方法。The object of the present invention is to provide a preparation method of teridinamine phosphate which is easy to obtain raw materials, simple in process, economical and environmentally friendly, and suitable for industrialization, in view of the defects in the prior art.
为实现上述发明目的,本发明采用了如下主要技术方案:一种磷酸泰地唑胺(I)的制备方法,In order to achieve the above object, the present invention adopts the following main technical solutions: a preparation method of teridinamine phosphate (I),
Figure PCTCN2015089734-appb-000005
Figure PCTCN2015089734-appb-000005
其制备步骤包括:通过式II化合物与式III化合物进行偶联反应生成磷酸泰地唑胺(I)。The preparation step comprises the steps of: coupling a compound of the formula II with a compound of the formula III to form teridinamine (I).
Figure PCTCN2015089734-appb-000006
Figure PCTCN2015089734-appb-000006
此外,本发明还提出如下附属技术方案:In addition, the present invention also proposes the following subsidiary technical solutions:
所述式II化合物中R为氢、甲基、乙基、丙基、异丙基、苯基或频哪基,相应的式II化合物依次为2-(2-甲基四唑-5-基)吡啶-5-硼酸、2-(2-甲基四唑-5-基)吡啶-5-硼酸二甲酯、2-(2-甲基四唑-5-基)吡啶-5-硼酸二乙酯、2-(2-甲基四唑-5-基)吡啶-5-硼酸二丙酯、2-(2-甲基四唑-5-基)吡啶-5-硼酸二异丙酯、2-(2-甲基四唑-5-基)吡啶-5-硼酸二苯酯或2-(2-甲基四唑-5-基)吡啶-5-硼酸频哪酯。In the compound of formula II, R is hydrogen, methyl, ethyl, propyl, isopropyl, phenyl or pinacol, and the corresponding compound of formula II is 2-(2-methyltetrazol-5-yl). Pyridine-5-boric acid, dimethyl 2-(2-methyltetrazol-5-yl)pyridine-5-borate, 2-(2-methyltetrazol-5-yl)pyridine-5-borate Ethyl ester, 2-(2-methyltetrazol-5-yl)pyridine-5-borate dipropyl ester, 2-(2-methyltetrazol-5-yl)pyridine-5-borate diisopropyl ester, 2-(2-methyltetrazol-5-yl)pyridine-5-boronic acid diphenyl ester or 2-(2-methyltetrazol-5-yl)pyridine-5-boronic acid pinamate.
所述式III化合物中的卤素X为溴或碘,相应的式III化合物依次为R-3-(3-氟-4-溴-苯基)-2-氧代-5-噁唑烷基甲醇磷酸酯或R-3-(3-氟-4-碘-苯基)-2-氧代-5-噁唑烷基甲醇磷酸酯。The halogen X in the compound of the formula III is bromine or iodine, and the corresponding compound of the formula III is, in turn, R-3-(3-fluoro-4-bromo-phenyl)-2-oxo-5-oxazolidinylalkylmethanol Phosphate or R-3-(3-fluoro-4-iodo-phenyl)-2-oxo-5-oxazole alkyl methanol phosphate.
所述偶联反应的原料式II化合物与式III化合物的投料摩尔比为1∶0.5-1.5,优选1∶0.9-1.1。The molar ratio of the compound of the formula II to the compound of formula III in the coupling reaction is from 1:0.5 to 1.5, preferably from 1:0.9 to 1.1.
所述偶联反应的催化剂为氯化钯、醋酸钯、双(二亚苄基丙酮)钯、四(三苯基膦)钯、[1,1′-双(二苯基膦)二茂铁]二氯化钯、双(三环己基膦)二氯化钯或双(三苯基膦)二氯化钯,优选四(三苯基膦)钯或[1,1′-双(二苯基膦)二茂铁]二氯化钯。The catalyst for the coupling reaction is palladium chloride, palladium acetate, bis(dibenzylideneacetone)palladium, tetrakis(triphenylphosphine)palladium, [1,1'-bis(diphenylphosphino)ferrocene Palladium dichloride, bis(tricyclohexylphosphine)palladium dichloride or bis(triphenylphosphine)palladium dichloride, preferably tetrakis(triphenylphosphine)palladium or [1,1'-bis(diphenyl) Phosphine) ferrocene] palladium dichloride.
所述偶联反应的碱促进剂为碳酸钾、碳酸钠、碳酸铯、氟化铯、醋酸钾或磷酸钾,优选碳酸铯或磷酸钾。The base promoter of the coupling reaction is potassium carbonate, sodium carbonate, barium carbonate, barium fluoride, potassium acetate or potassium phosphate, preferably barium carbonate or potassium phosphate.
所述偶联反应的溶剂为乙腈、1,4-二氧六环、甲苯、二甲苯、N,N-二甲基甲酰胺、N,N-二甲基乙酰胺或二甲亚砜,优选1,4-二氧六环或甲苯。The solvent for the coupling reaction is acetonitrile, 1,4-dioxane, toluene, xylene, N,N-dimethylformamide, N,N-dimethylacetamide or dimethyl sulfoxide, preferably 1,4-dioxane or toluene.
所述偶联反应的温度为50-150℃,优选80-130℃。The temperature of the coupling reaction is from 50 to 150 ° C, preferably from 80 to 130 ° C.
相比于现有技术,本发明所涉及的磷酸泰地唑胺(I)的制备方法,具有原料易得、工艺简洁和环保经济等特点,故而利于该原料药的工业化生产,促进其经济技术的发展。Compared with the prior art, the preparation method of the teridinamine phosphate (I) according to the invention has the characteristics of easy availability of raw materials, simple process and environmental protection economy, thereby facilitating the industrial production of the raw material drug and promoting its economic technology. development of.
具体实施方式detailed description
以下结合数个较佳实施例对本发明技术方案作进一步非限制性的详细说明。The technical solution of the present invention will be further described in detail below in conjunction with several preferred embodiments.
实施例一:Embodiment 1:
Figure PCTCN2015089734-appb-000007
Figure PCTCN2015089734-appb-000007
氮气氛下,于三颈反应瓶中加入2-(2-甲基四唑-5-基)吡啶-5-硼酸(II)(2.15g, 10.5mmol)、R-3-(3-氟-4-碘-苯基)-2-氧代-5-噁唑烷基甲醇磷酸酯(III)(4.17g,10mmol)、四(三苯基膦)钯(0.23g,0.2mmol)、1M磷酸钾溶液15mL以及甲苯30mL,升温至回流,保持回流反应10-12小时,TLC检测反应完成。加入乙酸乙酯30mL,依次用水及饱和食盐水洗涤,无水硫酸钠干燥,减压浓缩,所得油状物用正己烷和乙酸乙酯(1∶1,V/V)重结晶,真空干燥得白色固体磷酸泰地唑胺(I)3.82g,收率84.9%,1H NMR(DMSO-d6):d 8.92(s,1H),8.20(m,2H),7.74(t,1H),7.66(dd,1H),7.50(dd,1H),4.95(m,1H),4.46(s,3H),4.21(t,1H),4.05(m,2H),3.91(m,1H),FAB-MS m/z:451[M+H]+2-(2-methyltetrazol-5-yl)pyridin-5-boronic acid (II) (2.15 g, 10.5 mmol), R-3-(3-fluoro-) was added to a three-necked reaction flask under a nitrogen atmosphere. 4-iodo-phenyl)-2-oxo-5-oxazole alkyl methanol phosphate (III) (4.17 g, 10 mmol), tetrakis(triphenylphosphine)palladium (0.23 g, 0.2 mmol), 1 M phosphoric acid 15 mL of potassium solution and 30 mL of toluene were heated to reflux, and reflux reaction was maintained for 10-12 hours, and the reaction was confirmed by TLC. After adding 30 mL of ethyl acetate, the mixture was washed with EtOAc EtOAc EtOAc. Solid teridazole phosphate (I) 3.82g, yield 84.9%, 1 H NMR (DMSO-d6): d 8.92 (s, 1H), 8.20 (m, 2H), 7.74 (t, 1H), 7.66 ( Dd, 1H), 7.50 (dd, 1H), 4.95 (m, 1H), 4.46 (s, 3H), 4.21 (t, 1H), 4.05 (m, 2H), 3.91 (m, 1H), FAB-MS m/z: 451 [M+H] + .
实施例二:Embodiment 2:
Figure PCTCN2015089734-appb-000008
Figure PCTCN2015089734-appb-000008
氮气氛下,于三颈反应瓶中加入2-(2-甲基四唑-5-基)吡啶-5-硼酸频哪酯(II)(3.01g,10.5mmol)、R-3-(3-氟-4-溴-苯基)-2-氧代-5-噁唑烷基甲醇磷酸酯(III)(3.69g,10mmol)、[1,1′-双(二苯基膦)二茂铁]二氯化钯/二氯甲烷复合物(0.15g,0.2mmol)、醋酸钾(1.17g,12mmol)和1,4-二氧六环50mL,升温至110℃,搅拌反应4-5小时,TLC检测反应完成。加入乙酸乙酯50mL,依次用水及饱和食盐水洗涤,无水硫酸钠干燥,减压浓缩,所得油状物用正己烷和乙酸乙酯(1∶1,V/V)重结晶,真空干燥得白色固体磷酸泰地唑胺(I)4.02g,收率89.3%。2-(2-Methyltetrazol-5-yl)pyridin-5-boronic acid pinamate (II) (3.01 g, 10.5 mmol), R-3-(3) was added to a three-necked reaction flask under a nitrogen atmosphere. -Fluoro-4-bromo-phenyl)-2-oxo-5-oxazole alkyl methanol phosphate (III) (3.69 g, 10 mmol), [1,1'-bis(diphenylphosphine) dioxin Iron] palladium dichloride/dichloromethane complex (0.15 g, 0.2 mmol), potassium acetate (1.17 g, 12 mmol) and 1,4-dioxane 50 mL, heated to 110 ° C, stirred for 4-5 hours , TLC detects the completion of the reaction. After adding 50 mL of ethyl acetate, the mixture was washed with EtOAc EtOAc. Solid teridazole phosphate (I) 4.02 g, yield 89.3%.
实施例三:Embodiment 3:
Figure PCTCN2015089734-appb-000009
Figure PCTCN2015089734-appb-000009
氮气氛下,于三颈反应瓶中加入2-(2-甲基四唑-5-基)-5-溴-吡啶(IV)(2.4g,10mmol)、双频哪醇基二硼烷(1.27g,5mmol)、1,1’-双(二苯膦基)二茂铁二氯化钯(0.82g,1mmol)、醋酸钾(1.17g,12mmol)和1,4-二氧六环30mL,升温至110℃,搅拌反应4小时。降至室温,仍然在氮气氛下,向体系内加入R-3-(3-氟-4-溴-苯基)-2-氧代-5-噁唑烷基甲醇磷酸酯(III)(3.69g,10mmol)、1,4-二氧六环20mL和5M 磷酸钾0.5mL,再次升温至100℃,搅拌反应4小时,TLC检测反应完成。加入乙酸乙酯50mL,过滤,滤液依次用水及饱和食盐水洗涤,无水硫酸钠干燥,减压浓缩,所得油状物用正己烷和乙酸乙酯(1∶1,V/V)重结晶,真空干燥得白色固体磷酸泰地唑胺(I)3.34g,收率74.2%。2-(2-Methyltetrazol-5-yl)-5-bromo-pyridine (IV) (2.4 g, 10 mmol), bis-pinacol diborane (dimer) was added to a three-necked reaction flask under a nitrogen atmosphere. 1.27 g, 5 mmol), 1,1'-bis(diphenylphosphino)ferrocene palladium dichloride (0.82 g, 1 mmol), potassium acetate (1.17 g, 12 mmol) and 1,4-dioxane 30 mL The temperature was raised to 110 ° C and the reaction was stirred for 4 hours. At room temperature, still under the nitrogen atmosphere, add R-3-(3-fluoro-4-bromo-phenyl)-2-oxo-5-oxazolidine methanol phosphate (III) to the system (3.69 g, 10 mmol), 1,4-dioxane 20 mL and 5M Potassium phosphate (0.5 mL) was again heated to 100 ° C, and the reaction was stirred for 4 hours, and the reaction was confirmed by TLC. Ethyl acetate (50 mL) was added, and the filtrate was evaporated. EtOAcjjjjjjjjjjjjjj The white solid solution of tertidazole (I) was dried in white form, 3.34 g, yield 74.2%.
实施例四(中间体II的制备):Example 4 (Preparation of Intermediate II):
Figure PCTCN2015089734-appb-000010
Figure PCTCN2015089734-appb-000010
于三颈反应瓶中将2-(2-甲基四唑-5-基)-5-溴-吡啶(IV)(2.4g,10mmol)溶于无水四氢呋喃25mL中,降温至-55℃,滴加异丙基氯化镁(1M,15ml),滴毕后搅拌反应30分钟。向该反应体系中加入硼酸三甲酯(1.25g,12mmol),继续搅拌反应4-5小时。低温下用饱和氯化铵溶液淬灭反应,并将反应液倾入1N稀盐酸30mL中,室温反应1小时。用乙酸乙酯萃取三次,合并有机相,饱和食盐水洗涤,无水硫酸钠干燥。减压浓缩,所得固体先用石油醚洗涤,再用水重结晶,得到白色固体2-(2-甲基四唑-5-基)吡啶-5-硼酸(II)1.6g,收率78.0%,FAB-MS m/z:206[M+H]+2-(2-Methyltetrazol-5-yl)-5-bromo-pyridine (IV) (2.4 g, 10 mmol) was dissolved in 25 mL of anhydrous tetrahydrofuran in a three-necked reaction flask and cooled to -55 ° C. Isopropylmagnesium chloride (1 M, 15 ml) was added dropwise, and the reaction was stirred for 30 minutes after the dropwise addition. Trimethyl borate (1.25 g, 12 mmol) was added to the reaction system, and the reaction was further stirred for 4-5 hours. The reaction was quenched with a saturated ammonium chloride solution at a low temperature, and the reaction mixture was poured into 30 mL of 1N diluted hydrochloric acid, and reacted at room temperature for 1 hour. The organic layer was combined and washed with brine, dried over anhydrous sodium sulfate. After concentration under reduced pressure, the obtained solid was washed with petroleum ether and then recrystallized from water to give white solid 2-(2-methyltetrazol-5-yl)pyridin-5-boronic acid (II) 1.6 g, yield 78.0%. FAB-MS m/z: 206 [M+H] + .
实施例五(中间体II的制备):Example 5 (Preparation of Intermediate II):
Figure PCTCN2015089734-appb-000011
Figure PCTCN2015089734-appb-000011
于三颈反应瓶中加入2-(2-甲基四唑-5-基)-5-溴-吡啶(IV)(2.4g,10mmol)、双频哪醇基二硼烷(1.27g,5mmol)、1,1’-双(二苯膦基)二茂铁二氯化钯(0.82g,1mmol)、醋酸钾(1.17g,12mmol)和1,4-二氧六环50mL,升温至110℃,搅拌反应8-10小时,TLC检测反应结束。用乙酸乙酯萃取三次,合并有机相,盐水洗涤,无水硫酸钠干燥。浓缩,乙酸乙酯和正己烷(1∶4)重结晶,得灰白色固体2-(2-甲基四唑-5-基)吡啶-5-硼酸频哪酯(II)2.48g,收率86.4%,FAB-MS m/z:288[M+H]+2-(2-Methyltetrazol-5-yl)-5-bromo-pyridine (IV) (2.4 g, 10 mmol), bis-pinacolyl diborane (1.27 g, 5 mmol) was added to a three-necked reaction flask. , 1,1'-bis(diphenylphosphino)ferrocene palladium dichloride (0.82 g, 1 mmol), potassium acetate (1.17 g, 12 mmol) and 1,4-dioxane 50 mL, heated to 110 The reaction was stirred for 8-10 hours at °C, and the reaction was terminated by TLC. It was extracted three times with ethyl acetate. Concentration, ethyl acetate and n-hexane (1:4) were recrystallized to give 2-(2-methyltetrazol-5-yl)pyridin-5-boronic acid (II) 2.48 g as an off-white solid. %, FAB-MS m/z: 288 [M+H] + .
实施例六(中间体III的制备):Example 6 (Preparation of Intermediate III):
Figure PCTCN2015089734-appb-000012
Figure PCTCN2015089734-appb-000012
氮气保护下,于三颈反应瓶中加入R-缩水甘油对甲苯磺酸酯(TG)(2.28g,10mmol)和N,N-二甲基甲酰胺25mL,搅拌溶解后,加入碳酸铯(0.33g,1mmol)和3-氟-4-溴-苯基异氰酸酯(V)(2.15g,10mmol),加热至100℃,反应1小时后,TLC检测反应结束。减压回收溶剂,残留物用二氯甲烷和水溶解,分出有机相,水相用二氯甲烷萃取2次,减压浓缩,得到的油状物R-3-(3-氟-4-溴-苯基)-2-氧代-5-噁唑烷基甲醇对甲苯磺酸酯(VI),无需进一步纯化处理,直接加入1N盐酸在50℃下反应5小时,用二氯甲烷萃取3次,合并有机相,依次用饱和食盐水和水洗涤,无水硫酸钠干燥,减压浓缩。将浓缩物溶于磷酸三乙酯30mL中,室温下加入三氯氧磷(2.2mL,24mmol),搅拌2-3小时。加入30mL乙酸乙酯,搅拌半小时后,倾入50g冰水中,并在0℃下继续搅拌2小时,有白色固体析出,过滤,滤饼用丙酮洗涤,干燥,得类白色固体R-3-(3-氟-4-溴-苯基)-2-氧代-5-噁唑烷基甲醇磷酸酯(III)2.45g,收率66.4%,FAB-MS m/z:369[M+H]+Under nitrogen protection, R-glycidyl p-toluenesulfonate (TG) (2.28 g, 10 mmol) and N,N-dimethylformamide 25 mL were added to a three-necked reaction flask, stirred and dissolved, and then cesium carbonate (0.33) was added. g, 1 mmol) and 3-fluoro-4-bromo-phenylisocyanate (V) (2.15 g, 10 mmol) were heated to 100 ° C. After 1 hour of reaction, the reaction was terminated by TLC. The solvent was evaporated under reduced pressure. the residue was crystalljjjjjjjjjjjjjjjj -Phenyl)-2-oxo-5-oxazole alkyl methanol p-toluenesulfonate (VI), without further purification, directly added to 1N hydrochloric acid at 50 ° C for 5 hours, extracted with dichloromethane 3 times The organic phase was combined, washed sequentially with brine brine and brine The concentrate was dissolved in 30 mL of triethyl phosphate, and phosphorus oxychloride (2.2 mL, 24 mmol) was added at room temperature, and stirred for 2-3 hours. After adding 30 mL of ethyl acetate and stirring for half an hour, it was poured into 50 g of ice water, and stirring was continued at 0 ° C for 2 hours. A white solid was precipitated, filtered, and the filter cake was washed with acetone and dried to give a white solid. (3-Fluoro-4-bromo-phenyl)-2-oxo-5-oxazole alkyl methanol phosphate (III) 2.45 g, yield 66.4%, FAB-MS m/z: 369 [M+H ] + .
实施例六(中间体III的制备):Example 6 (Preparation of Intermediate III):
Figure PCTCN2015089734-appb-000013
Figure PCTCN2015089734-appb-000013
氮气保护下,于三颈反应瓶中加入R-缩水甘油对甲苯磺酸酯(TG)(2.28g,10mmol)和四氢呋喃50mL,搅拌溶解后,加入碘化锂(0.14g,1mmol)和3-氟-4-碘-苯基异氰酸酯(V)(2.63g,10mmol),加热至回流,反应2小时后,TLC检测反应结束。减压回收溶剂,残留物用二氯甲烷和水溶解,分出有机相,水相用二氯甲烷萃取2次,减压浓缩,得到的油状物R-3-(3-氟-4-碘-苯基)-2-氧代-5-噁唑烷基甲醇对甲苯磺酸酯(VI),无需进一步纯化处理,直接加入1N盐酸在50℃下反应5小时,用二氯甲烷萃取3次,合并有机相,依次用饱和食盐水和水洗涤,无水硫酸钠干燥,减压浓缩。将浓缩物溶于磷酸三乙酯30mL中,室温下加入三氯氧磷(2.2mL,24mmol),搅拌2-3小时。加入30mL乙酸乙酯,搅拌半小时后,倾入50g冰水中,并在0℃下继续搅拌2小时,有白色固体析出,过滤,滤饼用丙酮洗涤,干燥,得类白色固体R-3-(3-氟-4-碘-苯基)-2-氧代-5-噁唑烷基甲醇磷酸酯(III)2.65g,收率63.7%,FAB-MS m/z:417[M+H]+Under a nitrogen atmosphere, R-glycidyl p-toluenesulfonate (TG) (2.28 g, 10 mmol) and tetrahydrofuran 50 mL were added to a three-necked reaction flask, and after stirring and stirring, lithium iodide (0.14 g, 1 mmol) and 3- were added. Fluor-4-iodo-phenylisocyanate (V) (2.63 g, 10 mmol) was heated to reflux. After 2 hours of reaction, the reaction was terminated by TLC. The solvent was evaporated under reduced pressure. the residue was crystalljjjjjjjjjjjjjjjj -Phenyl)-2-oxo-5-oxazole alkyl methanol p-toluenesulfonate (VI), without further purification, directly added to 1N hydrochloric acid at 50 ° C for 5 hours, extracted with dichloromethane 3 times The organic phase was combined, washed sequentially with brine brine and brine The concentrate was dissolved in 30 mL of triethyl phosphate, and phosphorus oxychloride (2.2 mL, 24 mmol) was added at room temperature, and stirred for 2-3 hours. After adding 30 mL of ethyl acetate and stirring for half an hour, it was poured into 50 g of ice water, and stirring was continued at 0 ° C for 2 hours. A white solid was precipitated, filtered, and the filter cake was washed with acetone and dried to give a white solid. (3-Fluoro-4-iodo-phenyl)-2-oxo-5-oxazole alkyl methanol phosphate (III) 2.65 g, yield 63.7%, FAB-MS m/z: 417 [M+H ] + .
需要指出的是,上述实施例仅为说明本发明的技术构思及特点,其目的在于让熟悉此项技术的人士能够了解本发明的内容并据以实施,并不能以此限制本发 明的保护范围。凡根据本发明精神实质所作的等效变化或修饰,都应涵盖在本发明的保护范围之内。 It should be noted that the above embodiments are merely illustrative of the technical concept and features of the present invention, and the purpose of the present invention is to enable those skilled in the art to understand the contents of the present invention and implement the present invention. The scope of protection. Equivalent variations or modifications made in accordance with the spirit of the invention are intended to be included within the scope of the invention.

Claims (8)

  1. 一种磷酸泰地唑胺(I)的制备方法,A method for preparing tertimazine phosphate (I),
    Figure PCTCN2015089734-appb-100001
    Figure PCTCN2015089734-appb-100001
    其制备步骤包括:通过式II化合物与式III化合物进行偶联反应生成磷酸泰地唑胺(I),The preparation step comprises the steps of: coupling a compound of the formula II with a compound of the formula III to form tertidazole phosphate (I),
    Figure PCTCN2015089734-appb-100002
    Figure PCTCN2015089734-appb-100002
  2. 如权利要求1所述磷酸泰地唑胺的制备方法,其特征在于:所述式II化合物中R为氢、甲基、乙基、丙基、异丙基、苯基或频哪基,相应的式II化合物依次为2-(2-甲基四唑-5-基)吡啶-5-硼酸、2-(2-甲基四唑-5-基)吡啶-5-硼酸二甲酯、2-(2-甲基四唑-5-基)吡啶-5-硼酸二乙酯、2-(2-甲基四唑-5-基)吡啶-5-硼酸二丙酯、2-(2-甲基四唑-5-基)吡啶-5-硼酸二异丙酯、2-(2-甲基四唑-5-基)吡啶-5-硼酸二苯酯或2-(2-甲基四唑-5-基)吡啶-5-硼酸频哪酯。The method for preparing thetazolamide according to claim 1, wherein R in the compound of formula II is hydrogen, methyl, ethyl, propyl, isopropyl, phenyl or pinacol, correspondingly The compound of formula II is 2-(2-methyltetrazol-5-yl)pyridine-5-boronic acid, 2-(2-methyltetrazol-5-yl)pyridin-5-borate dimethyl ester, 2 -(2-methyltetrazol-5-yl)pyridine-5-borate diethyl ester, 2-(2-methyltetrazol-5-yl)pyridine-5-borate dipropyl ester, 2-(2- Methyltetrazole-5-yl)pyridine-5-borate diisopropyl ester, 2-(2-methyltetrazol-5-yl)pyridine-5-borate diphenyl ester or 2-(2-methyltetrayl) Imidazol-5-yl)pyridine-5-boronic acid pinamate.
  3. 如权利要求1所述磷酸泰地唑胺的制备方法,其特征在于:所述式III化合物中的卤素X为溴或碘,相应的式III化合物依次为R-3-(3-氟-4-溴-苯基)-2-氧代-5-噁唑烷基甲醇磷酸酯或R-3-(3-氟-4-碘-苯基)-2-氧代-5-噁唑烷基甲醇磷酸酯。The method for preparing tertidamine phosphate according to claim 1, wherein the halogen X in the compound of the formula III is bromine or iodine, and the corresponding compound of the formula III is R-3-(3-fluoro-4). -Bromo-phenyl)-2-oxo-5-oxazole alkyl methanol phosphate or R-3-(3-fluoro-4-iodo-phenyl)-2-oxo-5-oxazolidinyl Methanol phosphate.
  4. 如权利要求1所述磷酸泰地唑胺的制备方法,其特征在于:所述偶联反应的原料式II化合物与式III化合物的投料摩尔比为1∶0.5-1.5。The method for preparing tertidazole phosphate according to claim 1, characterized in that the molar ratio of the compound of the formula II to the compound of the formula III in the coupling reaction is from 1:0.5 to 1.5.
  5. 如权利要求1所述磷酸泰地唑胺的制备方法,其特征在于:所述偶联反应的催化剂为氯化钯、醋酸钯、双(二亚苄基丙酮)钯、四(三苯基膦)钯、[1,1′-双(二苯基膦)二茂铁]二氯化钯、双(三环己基膦)二氯化钯或双(三苯基膦)二氯化钯。The method for preparing thetazolamide according to claim 1, wherein the catalyst for the coupling reaction is palladium chloride, palladium acetate, bis(dibenzylideneacetone)palladium or tetrakis(triphenylphosphine). Palladium, [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride, bis(tricyclohexylphosphine)palladium dichloride or bis(triphenylphosphine)palladium dichloride.
  6. 如权利要求1所述磷酸泰地唑胺的制备方法,其特征在于:所述偶联反应的碱促进剂为碳酸钾、碳酸钠、碳酸铯、氟化铯、醋酸钾或磷酸钾。The method for preparing tertidamine phosphate according to claim 1, wherein the alkali promoter of the coupling reaction is potassium carbonate, sodium carbonate, cesium carbonate, cesium fluoride, potassium acetate or potassium phosphate.
  7. 如权利要求1所述磷酸泰地唑胺的制备方法,其特征在于:所述偶联反应的溶剂为乙腈、1,4-二氧六环、甲苯、二甲苯、N,N-二甲基甲酰胺、N,N-二甲基 乙酰胺或二甲亚砜。The method for preparing tertidamine phosphate according to claim 1, wherein the solvent for the coupling reaction is acetonitrile, 1,4-dioxane, toluene, xylene, N,N-dimethyl Formamide, N,N-dimethyl Acetamide or dimethyl sulfoxide.
  8. 如权利要求1所述磷酸泰地唑胺的制备方法,其特征在于:所述偶联反应的温度为50-150℃。 A method of producing tertimazine phosphate according to claim 1, wherein the temperature of the coupling reaction is from 50 to 150 °C.
PCT/CN2015/089734 2014-10-17 2015-09-16 Method for preparing tedizolid phosphate WO2016058467A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201410553205.2A CN104327119A (en) 2014-10-17 2014-10-17 Preparation method of tedizolid phosphate
CN201410553205.2 2014-10-17

Publications (1)

Publication Number Publication Date
WO2016058467A1 true WO2016058467A1 (en) 2016-04-21

Family

ID=52401934

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2015/089734 WO2016058467A1 (en) 2014-10-17 2015-09-16 Method for preparing tedizolid phosphate

Country Status (2)

Country Link
CN (1) CN104327119A (en)
WO (1) WO2016058467A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112500433A (en) * 2020-12-23 2021-03-16 桂林南药股份有限公司 Preparation method of tedizolid phosphate
CN113563679A (en) * 2021-08-31 2021-10-29 戴科元 Flame-retardant antibacterial PVC material and preparation method thereof
CN113979835A (en) * 2021-11-14 2022-01-28 重庆医科大学 Synthetic method of pazopanib trimer impurity intermediate
US11555033B2 (en) 2020-06-18 2023-01-17 Akagera Medicines, Inc. Oxazolidinone compounds, liposome compositions comprising oxazolidinone compounds and method of use thereof

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104496979A (en) * 2014-09-17 2015-04-08 博瑞生物医药技术(苏州)有限公司 Method for preparing oxazolidinone compound and intermediate thereof
WO2016041505A1 (en) * 2014-09-17 2016-03-24 正大天晴药业集团股份有限公司 Tedizolid phosphate, intermediate and preparation method thereof
CN104327119A (en) * 2014-10-17 2015-02-04 苏州明锐医药科技有限公司 Preparation method of tedizolid phosphate
CN105837634B (en) * 2015-01-30 2020-09-04 上海创诺制药有限公司 Tedizolid phosphate crystal and preparation method thereof
CN104592218B (en) * 2015-02-13 2015-11-04 江苏欧信医药化工有限公司 The synthetic method of a kind of safe ground azoles amine
CN104892592A (en) * 2015-03-30 2015-09-09 成都惟新医药科技有限公司 Preparation method for tedizolid
CN106146485B (en) * 2015-04-01 2021-04-30 上海迪赛诺化学制药有限公司 Method for preparing tedizolid and tedizolid crystal obtained by method
CN110078764B (en) * 2015-04-10 2021-10-26 博瑞生物医药(苏州)股份有限公司 Preparation method of oxazolidinone compound
CN106279282B (en) * 2015-05-21 2019-08-23 博瑞生物医药(苏州)股份有限公司 A kind of purification process of Tedizolid Phosphate
CN106608884A (en) * 2015-10-27 2017-05-03 博瑞生物医药(苏州)股份有限公司 Tedizolid system intermediate crystal form
CN106632298B (en) * 2015-11-03 2021-06-01 上海科胜药物研发有限公司 Preparation method and intermediate of tedizolid
CN105418681A (en) * 2015-12-15 2016-03-23 南京艾德凯腾生物医药有限责任公司 Preparation method of tedizolid phosphate
CN105753904B (en) * 2016-04-22 2017-12-08 南京济群医药科技股份有限公司 A kind of process for purification of Tedizolid Phosphate
CN107382995A (en) * 2017-09-01 2017-11-24 杭州新博思生物医药有限公司 One pot process safe ground azoles amine

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005058886A1 (en) * 2003-12-18 2005-06-30 Dong-A Pharm.Co.,Ltd. Novel oxazolidinone derivatives
WO2006038100A1 (en) * 2004-10-08 2006-04-13 Ranbaxy Laboratories Limited Oxazolidinone derivatives as antimicrobials
WO2009020616A1 (en) * 2007-08-06 2009-02-12 Micurx Pharmaceuticals, Inc. Antimicrobial ortho-fluorophenyl oxazolidinones for treatment of bacterial infections
WO2010042887A2 (en) * 2008-10-10 2010-04-15 Trius Therapeutics Methods for preparing oxazolidinones and compositions containing them
CN104327119A (en) * 2014-10-17 2015-02-04 苏州明锐医药科技有限公司 Preparation method of tedizolid phosphate

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101739923B1 (en) * 2009-02-03 2017-05-25 머크 샤프 앤드 돔 코포레이션 Crystalline form of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005058886A1 (en) * 2003-12-18 2005-06-30 Dong-A Pharm.Co.,Ltd. Novel oxazolidinone derivatives
WO2006038100A1 (en) * 2004-10-08 2006-04-13 Ranbaxy Laboratories Limited Oxazolidinone derivatives as antimicrobials
WO2009020616A1 (en) * 2007-08-06 2009-02-12 Micurx Pharmaceuticals, Inc. Antimicrobial ortho-fluorophenyl oxazolidinones for treatment of bacterial infections
WO2010042887A2 (en) * 2008-10-10 2010-04-15 Trius Therapeutics Methods for preparing oxazolidinones and compositions containing them
CN104327119A (en) * 2014-10-17 2015-02-04 苏州明锐医药科技有限公司 Preparation method of tedizolid phosphate

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WEON BIN INI ET AL.: "Discovery of torezolid as a novel 5-hydroxymethyl-oxazolidinone antibacterial agent", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 46, 18 January 2011 (2011-01-18), XP028185750, DOI: doi:10.1016/j.ejmech.2011.01.014 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11555033B2 (en) 2020-06-18 2023-01-17 Akagera Medicines, Inc. Oxazolidinone compounds, liposome compositions comprising oxazolidinone compounds and method of use thereof
US11566023B2 (en) 2020-06-18 2023-01-31 Akagera Medicines, Inc. Oxazolidinone compounds, liposome compositions comprising oxazolidinone compounds and method of use thereof
CN112500433A (en) * 2020-12-23 2021-03-16 桂林南药股份有限公司 Preparation method of tedizolid phosphate
CN113563679A (en) * 2021-08-31 2021-10-29 戴科元 Flame-retardant antibacterial PVC material and preparation method thereof
CN113979835A (en) * 2021-11-14 2022-01-28 重庆医科大学 Synthetic method of pazopanib trimer impurity intermediate
CN113979835B (en) * 2021-11-14 2023-09-26 重庆医科大学 Synthesis method of pazopanib trimer impurity intermediate

Also Published As

Publication number Publication date
CN104327119A (en) 2015-02-04

Similar Documents

Publication Publication Date Title
WO2016058467A1 (en) Method for preparing tedizolid phosphate
US10221155B2 (en) Method for preparing Alectinib
CN104496979A (en) Method for preparing oxazolidinone compound and intermediate thereof
TW201831461A (en) Process for preparing apalutamide
CN107176955A (en) A kind of Ba Rui replaces the preparation method of Buddhist nun
CN104447686B (en) Polysubstituted 2-pyrroles's pyridine derivate and preparation method thereof
CN106674264A (en) Synthetic method for (2,2,2-trifluoroethoxyl) phenylboronic acid compounds
CN103374039A (en) Synthesis method of tenofovir
WO2016041505A1 (en) Tedizolid phosphate, intermediate and preparation method thereof
WO2007105657A1 (en) Method of synthesizing oligomer compound with cross-coupling reaction
CN109867695B (en) Novel preparation method of pitavastatin calcium intermediate
CN103421050A (en) Ferrocene dicarboxylate compounds and synthetic method thereof
CN101531680B (en) Method for synthesizing (R)-9(2-(diethyl phosphonyl methoxyl) propyl)-adenine
CN104003943A (en) Preparation method for ticagrelor intermediate
CN106243079B (en) The Preparation Method And Their Intermediate compound of bicyclic alcohols
CN104496913B (en) A method of preparing 5- substitution -2,4- dimethyl sulphur-based pyrimidines
CN102786541A (en) Preparation method and application of potassium (iso)quinoline thifluoroborate
CN102531985B (en) Method for preparing ezetimibe key intermediate
CN104926674A (en) (Z)-3-dimethylamino-2-phenoxy-alpha, beta-unsaturated amide and preparation method thereof
CN105330525A (en) Preparation method of 7-hydroxy-1-indanone
CN105777631B (en) A kind of synthetic method of the bromo- 8- difluoro-methoxies -1,4- dihydroquinoline -3- carboxylic acid, ethyl esters of 1- cyclopropyl -4- oxos -7-
CN113045475A (en) Preparation method of 5-bromo-7-methylindole
CN104496940A (en) Method for preparing BCR-ABL inhibitor intermediate
CN105102417A (en) Method for producing 4-halosenecioic acid derivative
CN103073525A (en) Method for synthesizing (S)-(3,4-difluorophenyl)hexamethylene oxide

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15849995

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205N DATED 23.06.17)

122 Ep: pct application non-entry in european phase

Ref document number: 15849995

Country of ref document: EP

Kind code of ref document: A1